Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Aug 23, 2023 11:42pm
143 Views
Post# 35603124

RE:RE:RE:RE:RE:Government's site

RE:RE:RE:RE:RE:Government's site Parp inhibitors were approved from phase II for ovarian cancer.  They don't cure anyone but they can keep BRCA positive patients in remission for a few years.  Some nasty side-effects are possible. 

As for the time it takes to get on the trial, it took my wife about 8 months but waa because Dr Winer preferred immunotherapy and they kept telling us that there were no spots. She didn't get on the trial until I said it is TH1902 or nothing.  But by that time it was too late.  Tumors had already invaded one kidney,  the left main bronchus, the pancreas,  and blocked the bile ducts and the small intestine.  

You can get a patient on a trial within 2 or 3 weeks if they meet the criteria.   Just medical history or positive blood work can keep you off. Biopsy needs to be taken but the results won't keep you off. Ct Scan and eye test can be taken the day before.  If they really want to they  could get a patient on in a week.




Lee430 wrote: If I recall Wino or Scarlet was saying that if results are good in the PH2 trial we could get an approval for late stage therapy?
LouisW wrote: To me, it more like a Phase 1b/2 study.




<< Previous
Bullboard Posts
Next >>